ORMP - Oramed Pharmaceuticals, Inc
IEX Last Trade
2.385
-0.015 -0.629%
Share volume: 62,141
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$2.40
-0.02
-0.63%
Fundamental analysis
17%
Profitability
0%
Dept financing
12%
Liquidity
50%
Performance
27%
Performance
5 Days
-3.63%
1 Month
-1.65%
3 Months
6.70%
6 Months
-29.91%
1 Year
-28.01%
2 Year
-71.78%
Key data
Stock price
$2.38
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.67 - $3.67
52 WEEK CHANGE
-$0.31
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Nadav Kidron
Region: US
Website: http://www.oramed.com/
Employees: 19
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.oramed.com/
Employees: 19
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg
Recent news